[Federal Register Volume 65, Number 196 (Tuesday, October 10, 2000)]
[Notices]
[Page 60200]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-25893]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Availability for Licensing: Chromatin Insulator Protecting 
Expressed Genes of Interest for Human Gene Therapy or Other Mammalian 
Transgenic Systems

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health (NIH), Department of Health 
and Human Services (DHHS), seeks licensee(s) who can effectively pursue 
the preclinical, clinical and commercial development of the technology 
embodied in U.S. Patent 5,610,053 entitled ``DNA Sequence Which Acts as 
a Chromatin Insulator Element to Protect Expressed Genes from Cis-
acting Regulatory Sequences in Mammalian Cells,'' issued on March 11, 
1997. The invention describes the isolation, identification, and 
characterization of a DNA element residing in higher eukaryotic 
chromatin structural domains. All fields of use are available for 
licensing. The patent rights in this technology have been assigned to 
the United States of America.

ADDRESSES: Requests for copies of the issued patent, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: Girish C. Barua, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301/496-7735 ext. 266; 
Facsimile: 301/402-0220; E-mail: <a href="/cdn-cgi/l/email-protection#41232033342026012e256f2f28296f262e37"><span class="__cf_email__" data-cfemail="4c2e2d3e392d2b0c232862222524622b233a">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: The technology provides the isolation of a 
functional DNA sequence comprising a chromatin insulating element from 
a vertebrate system and provides the first employment of the pure 
insulator element as a functional insulator in mammalian cells. The 
technology further relates to a method for insulating the expression of 
a gene from the activity of cis-acting regulatory sequences in 
eukaryotic chromatin.
    This technology could be of major importance in providing a 
mechanism and a tool to restrict the action of cis-acting regulatory 
elements on genes whose activities or encoded products are needed or 
desired to be expressed in mammalian transgenic systems. This 
technology provides the first pure insulator element to function solely 
as an insulator element in human cells. Accordingly, this technology 
could have tremendous practical implications for transgenic technology 
and human gene therapies, either in vitro or in vivo.
    The technology further provides a method and constructs for 
insulating the expression of a gene or genes in transgenic animals such 
that the transfected genes will be protected and stably expressed in 
the tissues of the transgenic animal or its offspring. For example, 
even if the DNA of the construct integrates into areas of silent 
chromatin in the genomic DNA of the host animal, the gene will continue 
to be expressed. The invention could provide a means of improving the 
stable integration and expression of any transgenic construct of 
interest, with efficiencies higher than are achieved presently. Use of 
this invention may represent a large potential savings for licensee's 
constructing transgenic cell lines or animals.
    The NIH seeks licensee(s), who in accordance with requirements and 
regulations governing the licensing of government-owned inventions (37 
CFR part 404), have meritorious plan(s) for the development of the DNA 
Chromatin Insulator technology to a marketable status to meet the needs 
of the public.

    Dated: September 29, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-25893 Filed 10-6-00; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>